<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984383</url>
  </required_header>
  <id_info>
    <org_study_id>2017_13</org_study_id>
    <secondary_id>2018-A03087-48</secondary_id>
    <nct_id>NCT03984383</nct_id>
  </id_info>
  <brief_title>IL-33, Endocan and Endothelial Cells</brief_title>
  <acronym>IL-33</acronym>
  <official_title>Regulation of IL33, Endocan and Their Targets in Primary Human Endothelial Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the inflammatory response of endothelial cells to various&#xD;
      stimulations, in particular the production of IL33 and of endocan in response to allergens,&#xD;
      agonists of microorganisms and pollutants.&#xD;
&#xD;
      For that purpose, this project attempts to set up a biological collection of lung and&#xD;
      umbilical cord endothelial cells.&#xD;
&#xD;
      Lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer&#xD;
      surgery.&#xD;
&#xD;
      Umbilical cord-derived endothelial cells are taken from the umbilical cord collected during&#xD;
      the delivery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.</measure>
    <time_frame>change from Baseline at 48 hours after stimulation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in IL33 protein concentration between stimulated and unstimulated primary human lung endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in IL33 protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in endocan protein concentration between stimulated and unstimulated primary human lung endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in endocan protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.</measure>
    <time_frame>change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Endothelial Cell</condition>
  <arm_group>
    <arm_group_label>Lung-derived endothelial cells</arm_group_label>
    <description>Every patient of more than 18 years undergoing lung cancer surgery in the department of thoracic surgery of the University Hospital of Lille.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Umbilical cord-derived endothelial cells</arm_group_label>
    <description>Every patient of more than 18 years giving birth in the University Hospital of Lille in the absence of significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC the day of the childbirth.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Lung-derived endothelial cells : every patient of more than 18 years undergoing lung cancer&#xD;
        surgery in the department of thoracic surgery of the University Hospital of Lille.&#xD;
&#xD;
        Umbilical cord-derived endothelial cells : every patient of more than 18 years giving birth&#xD;
        in the University Hospital of Lille in the absence of significant materno-foetal disorder&#xD;
        (for example: meconium-stained amniotic fluid, chorioamniotis, placental thrombosis,&#xD;
        eclampsia etc.) or of infection for HIV, VHB, VHC or if unknown status for HIV, VHB, VHC&#xD;
        the day of the childbirth.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  signed consent&#xD;
&#xD;
          -  Pregnant woman for umbilical cord-derive-endothelial cells&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Refusal to participate to the study&#xD;
&#xD;
          -  Endothelial cord-drived endothelial cells :&#xD;
&#xD;
               -  significant materno-foetal disorder (for example: meconium-stained amniotic&#xD;
                  fluid, chorioamnionitis, placental thrombosis, eclampsia etc.)&#xD;
&#xD;
               -  infection for HIV, VHB, VHC&#xD;
&#xD;
               -  unknown status for HIV, VHB, VHC the day of the childbirth.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cécile Chenivesse</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Lille, Service de Pneumologie et Immuno-Allergologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cécile Chenivesse, MD, Ph</last_name>
    <phone>03 20 44 59 48</phone>
    <phone_ext>+33</phone_ext>
    <email>cecile.chenivesse@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hop Calmette Chu Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécile Chenivesse, MD, Ph</last_name>
      <phone>03 20 44 59 48</phone>
      <phone_ext>+33</phone_ext>
      <email>cecile.chenivesse@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Corine Glineur, Ph</last_name>
      <phone>03 20 87 71 83</phone>
      <phone_ext>+33</phone_ext>
      <email>corine.glineur@pasteur-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cécile Chenivesse, MD,Ph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endothelial cells</keyword>
  <keyword>inflammation</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>IL-33</keyword>
  <keyword>Endocan</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

